02-414-A1 sequence listing.TXT SEQUENCE LISTING

```
<110>
       Elan Pharmaceuticals, Inc.
       Varghese, John
Maillard, Michel
<120> Method for Treating Alzheimer's Disease Using Aryl Alkanoic Acid Amides
<130>
      MBHB-02-414-A1
       PCT/US03/18517
<150>
<151>
       2003-06-11
       US 60/387,880
<150>
       2002-06-11
<151>
<160>
<170>
       PatentIn version 3.3
<210>
       13
<211>
<212>
       PRT
<213>
       Artificial
<220>
<223>
       Synthetic peptide
<220>
<221>
<222>
       MISC_FEATURE
       (1)..(1)
<223>
      N-terminal biotin
<220>
<221>
      MISC_FEATURE
<222>
       (11)..(11)
<223>
      Covalent attachment of oregon green
<400>
Ser Glu Val Asn Leu Asp Ala Glu Phe Arg Cys Lys Lys
       2
13
<210>
<211>
<212>
       PRT
       Artificial
<213>
<220>
<223>
       Synthetic peptide
<220>
<221>
       MISC_FEATURE
<222>
<223>
       (1)..(1)
      N-terminal biotin
<220>
<221>
<222>
       MISC_FEATURE
       (11)..(11)
<223> Covalent attachment of oregon green
                                          Page 1
```

Rec'd POT/PTO 2 0 JAN 2006

#7

02-414-A1 sequence listing.TXT

```
<400> 2
Ser Glu Val Lys Met Asp Ala Glu Phe Arg Cys Lys Lys 1 10
<210>
      22
<211>
<212>
      PRT
<213>
      Artificial
<220>
       Synthetic peptide
<223>
<220>
<221>
       MISC_FEATURE
<222>
       (1)..(1)
<223>
       N-terminal biotin
<220>
       MISC_FEATURE
<221>
<222>
       (20)..(20)
<223>
       Covalent attachment of oregon green
<400>
       3
Gly Leu Asn Ile Lys Thr Glu Glu Ile Ser Glu Ile Ser Tyr Glu Val
Glu Phe Arg Cys Lys Lys
20
<210>
<211> 33
<212>
       PRT
      Artificial
<213>
<220>
<223>
       Synthetic peptide
<220>
<221>
       MISC_FEATURE
<222>
       (1)..(1)
<223>
       N-terminal biotin
<220>
<221>
      MISC_FEATURE
<222>
       (32)..(32)
      Covalent attachment of oregon green
<400> 4
Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile
Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe Cys Lys
                                         Page 2
```

```
Lys
       5
33
<210>
<211>
<212>
       PRT
       Artificial
<213>
<220>
<223>
       Synthetic peptide
<220>
<221>
<222>
       MISC_FEATURE
       (1)..(1)
       N-terminal biotin
<223>
<220>
<221>
       MISC_FEATURE
<222>
<223>
       (7)...(7)
       Oxidized cysteine
<220>
<221>
<222>
       MISC_FEATURE
       (19)..(19)
       Oxidized cysteine
<220>
<221>
<222>
       MISC_FEATURE
       (31)..(31)
       Covalent attachment of oregon green
<223>
<400>
Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala Cys Lys
Lys
<210>
       33
<211>
<212>
       PRT
      Artificial
<213>
<220>
<223>
       Synthetic peptide
```

<220> <221>

<222>

<223>

MISC_FEATURE

N-terminal biotin

(1)..(1)

Page 3

```
02-414-A1 sequence listing.TXT
Cys Gly Gly Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu 1 10 15
Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu 20 25 30
```

```
<210>
<211> 29
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<220>
<221> MISC_FEATURE <222> (1)..(1)
<223>
      N-terminal biotin
<400> 7
Cys Gly Gly Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu 1 10 15
```

Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Asn Leu 20 25

```
<210> 8
       9
<211>
<212> PRT
<213> Artificial
<220>
<223> Synthetic peptide
<220>
<221> MISC_FEATURE <222> (1)..(1)
<223>
      N-terminal biotin
<400>
Ser Glu Val Asn Leu Asp Ala Glu Phe 5
<210>
<211>
       30
<212> PRT
<213> Artificial
```

<400> 6

Phe

Page 4

02-414-A1 sequence listing.TXT

<220> <223> Synthetic peptide

<400> 9

Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile $1 \hspace{1.5cm} 10 \hspace{1.5cm} 15$

Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe 20 25 30